Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 84 Published: March 31, 2022 Report Code: GMDGDHC22075IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    https://www.ispeech.org/text.to.speech

Chemotherapy induced nausea and vomiting pipeline market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Key Targets in the Chemotherapy Induced Nausea and Vomiting Pipeline Market

The key targets in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor.

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Targets

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Chemotherapy Induced Nausea and Vomiting Pipeline Market

The key MoA in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist.

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by MoA

 Chemotherapy Induced Nausea and Vomiting Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Chemotherapy Induced Nausea and Vomiting Pipeline Market

The key RoA in the chemotherapy induced nausea and vomiting pipeline market are oral, intravenous, inhalational, buccal, transdermal, nasal, parenteral, subcutaneous, sublingual, suppository, and transmucosal. Oral has the highest number of pipeline markets.

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by RoA

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Chemotherapy Induced Nausea and Vomiting Pipeline Market

The key molecule type in the chemotherapy induced nausea and vomiting pipeline market is small molecule.

Key Companies in the Chemotherapy Induced Nausea and Vomiting Pipeline Market

The key companies in the chemotherapy induced nausea and vomiting pipeline market are Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc.

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Companies

Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Companies

To know about more key companies, download a free report sample

Market report overview

Key targets 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor
Key MoA 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist
Key RoA Oral, Intravenous, Inhalational, Buccal, Transdermal, Nasal, Parenteral, Subcutaneous, Sublingual, Suppository, and Transmucosal
Key molecule type Small Molecule
Key companies Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Acacia Pharma Ltd

AcuCort AB

Amzell BV

Aphios Corp

Arovella Therapeutics Ltd

Athenex Inc

Axim Biotechnologies Inc

Benuvia Therapeutics Inc

Bionorica SE

Camurus AB

Daewoong Pharmaceutical Co Ltd

Ethicann Pharmaceuticals Inc

Helsinn Group

Hoverink Biotechnologies Inc

IntelGenx Corp

Jiangsu Hengrui Medicine Co Ltd

LipoSeuticals Inc

LP Pharmaceutical (Xiamen) Co Ltd

Luxena Pharmaceuticals Inc

MannKind Corp

Senzer Ltd

Shackelford Pharma Inc

Skye Bioscience Inc

SoluBest Ltd

Starton Therapeutics Inc

Yichang Humanwell Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Nausea and Vomiting – Overview

Chemotherapy Induced Nausea and Vomiting – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Nausea and Vomiting – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Nausea and Vomiting – Companies Involved in Therapeutics Development

Acacia Pharma Ltd

AcuCort AB

Amzell BV

Aphios Corp

Arovella Therapeutics Ltd

Athenex Inc

Axim Biotechnologies Inc

Benuvia Therapeutics Inc

Bionorica SE

Camurus AB

Daewoong Pharmaceutical Co Ltd

Ethicann Pharmaceuticals Inc

Helsinn Group

Hoverink Biotechnologies Inc

IntelGenx Corp

Jiangsu Hengrui Medicine Co Ltd

LipoSeuticals Inc

LP Pharmaceutical (Xiamen) Co Ltd

Luxena Pharmaceuticals Inc

MannKind Corp

Senzer Ltd

Shackelford Pharma Inc

Skye Bioscience Inc

SoluBest Ltd

Starton Therapeutics Inc

Yichang Humanwell Pharmaceutical Co Ltd

Chemotherapy Induced Nausea and Vomiting – Drug Profiles

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(netupitant + palonosetron hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

AMZ-004 – Drug Profile

Product Description

Mechanism Of Action

APD-403 – Drug Profile

Product Description

Mechanism Of Action

History of Events

aprepitant – Drug Profile

Product Description

Mechanism Of Action

aprepitant – Drug Profile

Product Description

Mechanism Of Action

aprepitant – Drug Profile

Product Description

Mechanism Of Action

dexamethasone – Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol – Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol – Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol – Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol – Drug Profile

Product Description

Mechanism Of Action

dronabinol – Drug Profile

Product Description

Mechanism Of Action

dronabinol – Drug Profile

Product Description

Mechanism Of Action

dronabinol – Drug Profile

Product Description

Mechanism Of Action

History of Events

fosnetupitant chloride hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

frovatriptan dimeglumine – Drug Profile

Product Description

Mechanism Of Action

granisetron – Drug Profile

Product Description

Mechanism Of Action

History of Events

granisetron – Drug Profile

Product Description

Mechanism Of Action

History of Events

HR-20013 – Drug Profile

Product Description

Mechanism Of Action

LPI-1504 – Drug Profile

Product Description

Mechanism Of Action

LPI-1505 – Drug Profile

Product Description

Mechanism Of Action

NB-1222 – Drug Profile

Product Description

Mechanism Of Action

History of Events

olanzapine – Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron – Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

palonosetron – Drug Profile

Product Description

Mechanism Of Action

palonosetron hydrochloride LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

SPID-301 – Drug Profile

Product Description

Mechanism Of Action

Zindol – Drug Profile

Product Description

Mechanism Of Action

History of Events

Chemotherapy Induced Nausea and Vomiting – Dormant Projects

Chemotherapy Induced Nausea and Vomiting – Discontinued Products

Chemotherapy Induced Nausea and Vomiting – Product Development Milestones

Featured News & Press Releases

Mar 01, 2022: AcuCort is exempted from the application fee by the U.S. Food and Drug Administration

Feb 22, 2022: AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT

Feb 17, 2022: AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT

Dec 02, 2021: Helsinn announces European Commission approval of the liquid formulation of AKYNZEO (fosnetupitant/palonosetron)

Nov 30, 2021: ESMO: Fosnetupitant is valuable in the prophylaxis of acute, delayed, and beyond delayed cinv

Oct 05, 2021: AcuCort’s drug ISICORT demonstrates a three-year shelf life

Oct 05, 2021: REDUVO- A major milestone for Tetra Bio-Pharma

Sep 03, 2021: AcuCort receives a second US patent protection for its drug ISICORT

Jun 16, 2021: Starton Therapeutics phase 2 TROPIC-I clinical study will be first to use total control primary endpoint in superiority study

Jun 02, 2021: Health Canada accepts new drug submission for REDUVO as a treatment for patients with chemotherapy-induced nausea and vomiting

May 05, 2021: DanCann Pharma have signed a definitive distribution agreement with Tetra Bio-Pharma for the exclusive distribution of Reduvo Adversa and Qixleef in Scandinavia and Germany

May 03, 2021: Tetra Bio-Pharma granted a drug establishment license to distribute REDUVO soft gel capsules in Canada

Apr 26, 2021: AcuCort progresses into a new phase and strengthens the commercialization team

Apr 14, 2021: Tetra Bio-Pharma provides update on its New Drug Submission application in Canada

Apr 13, 2021: Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Acacia Pharma Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by AcuCort AB, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Amzell BV, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Aphios Corp, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Arovella Therapeutics Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Athenex Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Axim Biotechnologies Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Benuvia Therapeutics Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Bionorica SE, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Camurus AB, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Ethicann Pharmaceuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Helsinn Group, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Hoverink Biotechnologies Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by IntelGenx Corp, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by LipoSeuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by LP Pharmaceutical (Xiamen) Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Luxena Pharmaceuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by MannKind Corp, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Senzer Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Shackelford Pharma Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Skye Bioscience Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by SoluBest Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Starton Therapeutics Inc, 2022

Chemotherapy Induced Nausea and Vomiting – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, 2022

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, 2022 (Contd..1)

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, 2022 (Contd..2)

Chemotherapy Induced Nausea and Vomiting – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

The key targets in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor.

The key MoA in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist.

The key RoA in the chemotherapy induced nausea and vomiting pipeline market are oral, intravenous, inhalational, buccal, transdermal, nasal, parenteral, subcutaneous, sublingual, suppository, and transmucosal.

The key molecule type in the chemotherapy induced nausea and vomiting pipeline market is small molecule.

The key companies in the chemotherapy induced nausea and vomiting pipeline market are Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.